![]() ![]() It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. This article by Simply Wall St is general in nature. Alternatively, email editorial-team (at). Have feedback on this article? Concerned about the content? Get in touch with us directly. This may not be consistent with full year annual report figures. ![]() NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future. īut ultimately it is the future, not the past, that will determine how well the owners of this business will do. To that end, you should be aware of the 4 warning signs we've spotted with Leap Therapeutics. But to understand Leap Therapeutics better, we need to consider many other factors. It's always worth thinking about the different groups who own shares in a company. This holding is probably worth investigating further. This may be a strategic interest and the two companies may have related business interests. Public companies currently own 10% of Leap Therapeutics stock. Alternatively, those holders might be exiting the investment after taking it public. ![]() Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. This suggests they can be influential in key policy decisions. Private equity firms hold a 17% stake in Leap Therapeutics. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. The general public, who are usually individual investors, hold a 32% stake in Leap Therapeutics. You can click here to see if those insiders have been buying or selling. Many investors in smaller companies prefer to see the board more heavily invested. It seems the board members have no more than US$2.9k worth of shares in the US$101m company. Our most recent data indicates that insiders own less than 1% of Leap Therapeutics, Inc. However, on some occasions too much power is concentrated within this group. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. Notably, sometimes top-level managers are on the board themselves. The company management answer to the board and the latter should represent the interests of shareholders. The definition of an insider can differ slightly between different countries, but members of the board of directors always count. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future. ![]() While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. Looking at the shareholder registry, we can see that 50% of the ownership is controlled by the top 13 shareholders, meaning that no single shareholder has a majority interest in the ownership. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |